Addex Therapeutics (ADXN) Cash from Investing Activities (2019 - 2024)

Addex Therapeutics has reported Cash from Investing Activities for 6 years, with the latest figure at -$5320.8 billion in Q4 2024.

• Quarterly Cash from Investing Activities fell 83827.03% year-over-year to -$5320.8 billion in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $64.7 billion (up 89767.97% YoY) and the FY2025 annual result came in at -$820996.0, down 115.55% from the prior year.
• Cash from Investing Activities eased to -$5320.8 billion in Q4 2024 per ADXN's latest filing, from $5379.9 billion in the prior quarter.
• Over five years, Cash from Investing Activities peaked at $5379.9 billion in Q3 2024 and troughed at -$5320.8 billion in Q4 2024.
• A 5-year average of $3.9 billion and a median of -$2669.4 in 2023 frame the typical range for Cash from Investing Activities.
• The sharpest annual moves came in 2023 and 2024: Cash from Investing Activities surged 68023499414.92% in 2023, then slumped 83827.03% in 2024.
• Over 5 years, Cash from Investing Activities stood at -$53189.5 in 2020, then soared by 50.25% to -$26460.8 in 2021, then surged by 99.96% to -$9.34 in 2022, then soared by 68023499414.92% to $6.4 billion in 2023, then plunged by 83827.03% to -$5320.8 billion in 2024.
• According to Business Quant data, Cash from Investing Activities over the past three periods registered -$5320.8 billion, $5379.9 billion, and $6.4 billion for Q4 2024, Q3 2024, and Q4 2023 respectively.